VOYAGER THERAPEUTICS INC. - COMMON STOCK

Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors

14 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

08 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

01 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

11 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target

04 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy

03 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Participate in Upcoming Investor Conferences

27 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs

07 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

04 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

03 Aug 2022 10:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update

02 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors

28 Jul 2022 06:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs

19 May 2022 05:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting

16 May 2022 05:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

04 May 2022 15:01:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting

03 May 2022 06:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

22 Mar 2022 06:00:01 By Nasdaq GlobeNewswire